November 22nd 2024
These findings further suggest the implications of acne vulgaris treatment on the skin barrier.
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Calming inflammation in common skin conditions
June 11th 2018Publishing new research findings certainly has its benefits, but how physicians use that information and their personal experience in clinical practice can prove to be more insightful. In this article, we feature three physicians who participated in the rapid-fire Q&A “60 Tips in 60 Minutes” from the Winter Clinical Dermatology Conference held in January in Hawaii.
Calming inflammation in common skin conditions
June 7th 2018Publishing new research findings has its benefits, but how physicians use that information and their personal experience in clinical practice can prove to be more insightful. In this table on page 98 of Dermatology Times June issue, we feature insights from three physicians who participated in the rapid-fire Q&A “60 Tips in 60 Minutes” from this year's Winter Clinical Dermatology Conference.
Managing acne female-to-male transgender persons
May 1st 2018As both severe acne and transgenderism are independently associated with higher rates of depression and suicide, it may be advisable that transgender adolescents are monitored for acne once testosterone treatment has begun. Given the potential risks - some 41% of transgender adults have at some point attempted suicide - acne should be treated even if only mild, says Dr. Lucía Campos-Munoz.
Spironolactone for hormonal acne
February 17th 2018Female patients with hormonal acne that typically flares before or after menstrual cycles may be ideal candidates for spironolactone, said Emmy M. Graber, M.D., president of the Dermatology Institute of Boston who spoke at AAD 2018 in San Diego this week.
Adult acne could be more traumatizing than teen acne
February 15th 2018The presence of adult acne, especially among women, is increasing, shows an Italian study that points to job stress for exasperating the condition in adults who are harder hit by the psychological, social and emotional effects of the condition as compared to teens.
From scars to active acne: Technological treatment for hard-to-treat cases
November 29th 2017Lasers and photodynamic therapy are practical treatment options for acne patients who fail or aren’t compliant with traditional first-line therapies. Today’s energy devices might also enhance acne treatment as adjuvant therapy, a review shows.
Compelling research lacking in laser-based acne treatment
November 29th 2017Dermatologists and others are increasingly using lasers and light-based therapies to treat acne, but the literature proving efficacy among these therapies is limited by few high-powered trials and lots of small, low-quality studies.